LIVANOVA PLC (LIVN)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for LIVN
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| LIVN | Chair of the Board | 57 | ["Chair of the Board of a global medical technology company","Chief Executive Officer and Executive Director of Entain Group PLC","Non-Executive Director of Entain","Chief Operating Officer and Chief Executive Officer of multiple business units at Modern Times Group AB","Senior Managing Director at Accenture","Master of Science degree in Business Administration with a concentration in Finance"] | ["Remuneration and Nomination Committee","Audit Committee"] | 2026 |
Biography sourced from the proxy statement filing.
Jette Nygaard-Andersen serves as Chair of the Board of Danish medical device company, Coloplast A/S ( Coloplast ), a position she assumed in May 2025. She has served as a Non-Executive Director of Coloplast since 2015, including as Chair of its Remuneration and Nomination Committee and as a member of its Audit Committee. Prior to her current role as Chair of the Board of Coloplast, Ms. Nygaard-Andersen served as Chief Executive Officer and Executive Director of Entain Group PLC ( Entain ), a large sports betting and gaming company, from 2021 to 2023 after serving as a Non-Executive Director of Entain from 2019 to 2021. During her time as Chief Executive Officer at Entain, she led a comprehensive strategic and operational transformation of the business, delivering significant revenue and EBITDA growth, and overseeing numerous strategic acquisitions. Before joining Entain, Ms. Nygaard-Andersen spent 16 years at Modern Times Group AB, a Nasdaq Nordic-listed European media, entertainment, and gaming group, where she progressed through a series of senior executive positions, serving as Chief Operating Officer and, subsequently, as Chief Executive Officer of multiple business units. Earlier in her career, she served as Senior Managing Director at Accenture, leading the firm s Telecommunications, Media, and Technology & Strategy practice. She holds a Master of Science degree in Business Administration, with a concentration in Finance, from the University of Copenhagen, where she graduated with distinction. Other Current Public Company Directorships: Coloplast (CLPBY) Director Skills: As the Chair of the Board of a global medical technology company and a seasoned chief executive with more than 25 years of leadership experience across complex, highly regulated, international businesses, Ms. Nygaard-Andersen brings to the Board a combination of active MedTech governance expertise and executive leadership. Ms. Nygaard-Andersen has a demonstrated track record of driving enterprise-wide transformation in demanding operating environments, including through governance strengthening, technology enablement, and disciplined capital allocation, and her extensive experience overseeing strategic mergers and acquisitions across multiple industries and geographies provides applicable expertise in business development. She brings deep international perspective, having led organizations spanning the United States, Europe, and emerging markets, and she has broad public company board experience, including long-standing service on the audit, remuneration, and nomination committees of a major publicly traded global company.